Aptinyx (NASDAQ:APTX) Posts Earnings Results, Beats Expectations By $0.16 EPS

Share on StockTwits

Aptinyx (NASDAQ:APTX) issued its earnings results on Monday. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.16, Bloomberg Earnings reports. The firm had revenue of $0.93 million during the quarter, compared to analyst estimates of $0.95 million. Aptinyx had a negative net margin of 1,166.40% and a negative return on equity of 37.53%.

APTX stock opened at $3.22 on Wednesday. The company has a 50-day moving average price of $3.62. The company has a market capitalization of $118.47 million, a P/E ratio of -1.22 and a beta of -0.03. Aptinyx has a 1-year low of $2.88 and a 1-year high of $32.25.

A number of brokerages have recently issued reports on APTX. Cantor Fitzgerald reissued a “buy” rating on shares of Aptinyx in a research note on Tuesday, April 30th. Svb Leerink began coverage on shares of Aptinyx in a research note on Thursday, June 20th. They set an “outperform” rating and a $12.00 target price for the company. Zacks Investment Research raised shares of Aptinyx from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research note on Tuesday, July 16th. JPMorgan Chase & Co. downgraded Aptinyx from a “neutral” rating to an “underweight” rating in a report on Tuesday. Finally, Cowen restated a “buy” rating on shares of Aptinyx in a report on Monday, June 10th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Aptinyx presently has a consensus rating of “Buy” and an average price target of $12.71.

About Aptinyx

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

See Also: Why do companies issue convertible shares?

Earnings History for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Cheesecake Factory Inc  Expected to Announce Quarterly Sales of $594.56 Million
Cheesecake Factory Inc Expected to Announce Quarterly Sales of $594.56 Million
$0.14 EPS Expected for BJ’s Restaurants, Inc.  This Quarter
$0.14 EPS Expected for BJ’s Restaurants, Inc. This Quarter
$278.76 Million in Sales Expected for BJ’s Restaurants, Inc.  This Quarter
$278.76 Million in Sales Expected for BJ’s Restaurants, Inc. This Quarter
Criteo SA  Expected to Post Earnings of $0.49 Per Share
Criteo SA Expected to Post Earnings of $0.49 Per Share
Municipal Employees Retirement System of Michigan Trims Stock Position in Dean Foods Co
Municipal Employees Retirement System of Michigan Trims Stock Position in Dean Foods Co
Municipal Employees Retirement System of Michigan Reduces Holdings in Pennsylvania R.E.I.T.
Municipal Employees Retirement System of Michigan Reduces Holdings in Pennsylvania R.E.I.T.


© 2006-2019 Ticker Report